By Anna Smith A new study in the BMJ has identified two new drugs, mAb114 and REGN-EB3, that can dramatically cut mortality from Ebola, and both are being immediately offered to all patients in an effort to control the Democratic Republic of Congo’s (DRC) worst-ever outbreak. The trial initially compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3, and preliminary data convinced the trial’s monitoring board to stop the study and randomize all remaining patients to either mAb114 or REGN-EB3. Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was ‘not far behind’. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%. Both drugs are monoclonal antibodies, proteins that bind to other proteins on the outer shell of the Ebola ...
As dreaded by the WHO, the first possible case of Ebola of a doctor presenting Ebola symptoms in eastern Democratic Republic of Congo, a violence-hit unapproachable area.
Four additional untried treatment solutions for the Ebola virus danger have received a green signal from the Democratic Republic of Congo as a move from the health ministry in its efforts to control the virus’ spread.
The health ministry of the DRC announced on 10 August that four new cases of Ebola virus were reported in eastern Democratic Republic of Congo.
On July 6th, the health ministry of Congo announced that health workers in were setting up refrigerators for maintaining an Ebola vaccine under cold conditions in order to tackle an Ebola outbreak, which was believed to have affected an estimated 43 people.
WHO officials have not yet pinpointed the strain of Ebola that is responsible for the death of 20 people and has infected four more, including two health workers. They are uncertain whether it could be the Zaire, Sudan or Bundibugyo strain.
In the latest Ebola outbreak, a total of 61 cases were recorded and 28 lives were claimed in the Congo region. But now the World Health Organization has reported that the spread of this Ebola outbreak has "largely been contained" after the success of Merck's late-stage vaccination campaign for more than a month.
A new study was conducted by Paolo Bocchini, associate professor of civil and environmental engineering, Javier Buceta, an associate professor of bioengineering, and postdoctoral researcher Graziano Fiorillo. They were affiliated with the Lehigh University in Bethlehem, PA. They hypothesized that, since fruit bats carry the Ebola virus, tracking down their migratory patterns might give information about the time and location of the next outbreak.
As the Democratic Republic of Congo deals with a rising death toll owing to the latest outbreak of Ebola, health officials are moving fast to counter the fatal effects of the deadly virus. Plans are afoot to implement the experimental vaccine developed by Merck & Co to confront the overwhelming challenges posed by the virus.
The Government of the Democratic Republic of the Congo declared a new outbreak of Ebola virus disease (EVD) in Bikoro in Equateur Province today (8 May). The outbreak declaration occurred after laboratory results confirmed two cases of EVD.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.